Regulation	O
of	O
fas-ligand	O
expression	O
during	O
activation-induced	O
cell	O
death	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
via	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

T	O
cell	O
receptor	O
engagement	O
activates	O
transcription	B-protein
factors	I-protein
important	O
for	O
cytokine	B-DNA
gene	I-DNA
regulation	O
.	O

Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation-induced	O
apoptosis	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
is	O
dependent	O
on	O
FasL	O
transcription	O
and	O
expression	O
.	O

Here	O
we	O
demonstrate	O
that	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
many	O
cytokine	B-DNA
genes	I-DNA
expressed	O
in	O
activated	B-cell_type
lymphocytes	I-cell_type
,	O
also	O
plays	O
a	O
role	O
in	O
T	O
cell	O
activation-induced	O
FasL	B-protein
expression	O
.	O

Inhibition	O
of	O
NF-kappaB	B-protein
activity	O
in	O
a	O
T	B-cell_line
cell	I-cell_line
hybridoma	I-cell_line
leads	O
to	O
decreased	O
FasL	B-protein
expression	O
and	O
apoptosis	O
upon	O
T	B-protein
cell	I-protein
receptor	I-protein
stimulation	O
.	O

We	O
identified	O
the	O
NF-kappaB	B-DNA
site	I-DNA
in	O
the	O
FasL	B-DNA
promoter	I-DNA
that	O
contributes	O
to	O
such	O
regulation	O
.	O

Co-expression	O
of	O
p65	B-protein
(	I-protein
Rel	I-protein
A	I-protein
)	I-protein
with	O
the	O
FasL	B-DNA
promoter	I-DNA
enhanced	O
its	O
activity	O
,	O
and	O
co-expression	O
of	O
IkappaB	B-protein
dramatically	O
inhibited	O
the	O
inducible	B-DNA
promoter	I-DNA
activity	O
.	O

In	O
contrast	O
,	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
is	O
not	O
required	O
for	O
activation-induced	O
FasL	B-protein
promoter	O
activity	O
.	O

These	O
results	O
define	O
a	O
role	O
for	O
NF-kappaB	B-protein
in	O
mediating	O
FasL	B-protein
expression	O
during	O
T	O
cell	O
activation	O
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

274	NULL
,	NULL
No	NULL
.	NULL

2	NULL
,	NULL
Issue	NULL
of	NULL
January	NULL
8	NULL
,	NULL
pp	NULL
.	NULL

987-992	NULL
,	NULL
1999	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Regulation	NULL
of	NULL
Fas-Ligand	NULL
Expression	NULL
during	NULL
Activation-induced	NULL
Cell	NULL
Death	NULL
in	NULL
T	NULL
Lymphocytes	NULL
via	NULL
Nuclear	NULL
Factor	NULL
«	NULL
B*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
July	NULL
1	NULL
,	NULL
1998	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
October	NULL
7	NULL
,	NULL
1998	NULL
)	NULL
Shailaja	NULL
Kasibhatlat	NULL
#	NULL
,	NULL
Laurent	NULL
Genestier	NULL
,	NULL
and	NULL
Douglas	NULL
R.	NULL
Green	NULL
From	NULL
the	NULL
Division	NULL
of	NULL
Cellular	NULL
Immunology	NULL
,	NULL
La	NULL
Jolla	NULL
Institute	NULL
for	NULL
Allergy	NULL
and	NULL
Immunology	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
California	NULL
92121	NULL
T	NULL
cell	NULL
receptor	NULL
engagement	NULL
activates	NULL
transcription	NULL
factors	NULL
important	NULL
for	NULL
cytokine	NULL
gene	NULL
regulation	NULL
.	NULL

Addi-tionally	NULL
,	NULL
this	NULL
signaling	NULL
pathway	NULL
also	NULL
leads	NULL
to	NULL
activation-induced	NULL
apoptosis	NULL
in	NULL
T	NULL
lymphocytes	NULL
that	NULL
is	NULL
dependent	NULL
on	NULL
FasL	NULL
transcription	NULL
and	NULL
expression	NULL
.	NULL

Here	NULL
we	NULL
demonstrate	NULL
that	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-xB	NULL
)	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
many	NULL
cytokine	NULL
genes	NULL
expressed	NULL
in	NULL
activated	NULL
lymphocytes	NULL
,	NULL
also	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
T	NULL
cell	NULL
activation-induced	NULL
FasL	NULL
expression	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
hybridoma	NULL
leads	NULL
to	NULL
decreased	NULL
FasL	NULL
expression	NULL
and	NULL
apoptosis	NULL
upon	NULL
T	NULL
cell	NULL
receptor	NULL
stimulation	NULL
.	NULL

We	NULL
identified	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
FasL	NULL
promoter	NULL
that	NULL
contributes	NULL
to	NULL
such	NULL
regulation	NULL
.	NULL

Co-expression	NULL
of	NULL
p65	NULL
(	NULL
Rel	NULL
A	NULL
)	NULL
with	NULL
the	NULL
FasL	NULL
promoter	NULL
enhanced	NULL
its	NULL
activity	NULL
,	NULL
and	NULL
co-expression	NULL
of	NULL
IxB	NULL
dramatically	NULL
inhibited	NULL
the	NULL
inducible	NULL
promoter	NULL
activity	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
is	NULL
not	NULL
required	NULL
for	NULL
activation-induced	NULL
FasL	NULL
promoter	NULL
activity	NULL
.	NULL

These	NULL
results	NULL
define	NULL
a	NULL
role	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
mediating	NULL
FasL	NULL
expression	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Activation-induced	NULL
cell	NULL
death	NULL
(	NULL
AICD	NULL
)	NULL
is	NULL
a	NULL
major	NULL
mechanism	NULL
to	NULL
maintain	NULL
immune	NULL
homeostasis	NULL
.	NULL

AICD	NULL
occurs	NULL
in	NULL
mature	NULL
T	NULL
lymphocytes	NULL
to	NULL
limit	NULL
antigen-specific	NULL
responses	NULL
.	NULL

Upon	NULL
clearing	NULL
antigens	NULL
and/or	NULL
pathogens	NULL
from	NULL
the	NULL
host	NULL
,	NULL
activated	NULL
T	NULL
cells	NULL
are	NULL
deleted	NULL
via	NULL
the	NULL
activation	NULL
of	NULL
apoptosis	NULL
,	NULL
which	NULL
we	NULL
and	NULL
others	NULL
have	NULL
shown	NULL
to	NULL
be	NULL
dependent	NULL
upon	NULL
Fas	NULL
ligand	NULL
(	NULL
FasL	NULL
,	NULL
CD95	NULL
ligand	NULL
)	NULL
expression	NULL
and	NULL
ligation	NULL
of	NULL
its	NULL
receptor	NULL
,	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
(	NULL
1-5	NULL
)	NULL
.	NULL

However	NULL
,	NULL
despite	NULL
our	NULL
understanding	NULL
of	NULL
the	NULL
importance	NULL
of	NULL
FasL	NULL
in	NULL
controlling	NULL
homeostasis	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
its	NULL
transcriptional	NULL
regulation	NULL
.	NULL

T	NULL
cell	NULL
receptor	NULL
ligation	NULL
activates	NULL
a	NULL
cascade	NULL
of	NULL
signaling	NULL
events	NULL
which	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
cytokine	NULL
gene	NULL
expression	NULL
including	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Signaling	NULL
events	NULL
post-TCR	NULL
ligation	NULL
and	NULL
phospho-lipase	NULL
C-y1	NULL
lead	NULL
to	NULL
two	NULL
distinct	NULL
signals	NULL
:	NULL
activation	NULL
of	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
pathway	NULL
and	NULL
release	NULL
of	NULL
intracellular	NULL
Ca**	NULL
stores	NULL
,	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
National	NULL
Service	NULL
Award	NULL
AG	NULL
00252-01	NULL
(	NULL
to	NULL
S.	NULL
K	NULL
)	NULL
,	NULL
Human	NULL
Frontier	NULL
Science	NULL
Program	NULL
(	NULL
to	NULL
L.	NULL
G.	NULL
)	NULL
,	NULL
and	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
GM	NULL
52785	NULL
and	NULL
CA	NULL
69831	NULL
(	NULL
to	NULL
D.	NULL
R.	NULL
G.	NULL
)	NULL
This	NULL
is	NULL
publication	NULL
255	NULL
from	NULL
La	NULL
Jolla	NULL
Institute	NULL
for	NULL
Allergy	NULL
and	NULL
Immunology	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

$	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Div	NULL
.	NULL

of	NULL
Cellular	NULL
Immunology	NULL
,	NULL
La	NULL
Jolla	NULL
Institute	NULL
for	NULL
Allergy	NULL
and	NULL
Immunology	NULL
,	NULL
10855	NULL
Science	NULL
Center	NULL
Dr.	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
92121	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
619-678-4680	NULL
;	NULL
Fax	NULL
:	NULL
619-558-3526	NULL
;	NULL
E-mail	NULL
:	NULL
skasibhatla	NULL
@	NULL
liai.org	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
AICD	NULL
,	NULL
activation-induced	NULL
cell	NULL
death	NULL
;	NULL
IL-2	NULL
,	NULL
interleukin	NULL
2	NULL
;	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
NF-AT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
;	NULL
NF-B	NULL
,	NULL
nuclear	NULL
factor	NULL
xB	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
RT-PCR	NULL
,	NULL
reverse	NULL
transcription-polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
kbp	NULL
,	NULL
kilobase	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
;	NULL
hFasL	NULL
,	NULL
human	NULL
FasL	NULL
;	NULL
DN-MEKK	NULL
,	NULL
dominant	NULL
negative	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
kinase	NULL
.	NULL

subsequent	NULL
Ca**	NULL
influx	NULL
,	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
serine	NULL
phos-phatase	NULL
,	NULL
calcineurin	NULL
(	NULL
7	NULL
)	NULL
.	NULL

These	NULL
two	NULL
signals	NULL
can	NULL
be	NULL
mimicked	NULL
by	NULL
treatment	NULL
of	NULL
cells	NULL
with	NULL
the	NULL
pharmacological	NULL
agents	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
and	NULL
ionomycin	NULL
.	NULL

Calcineurin-mediated	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NF-AT	NULL
)	NULL
and	NULL
its	NULL
role	NULL
in	NULL
cytokine	NULL
gene	NULL
expression	NULL
is	NULL
well	NULL
established	NULL
(	NULL
7-9	NULL
)	NULL
,	NULL
and	NULL
more	NULL
recently	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
NF-AT	NULL
sites	NULL
in	NULL
the	NULL
FasL	NULL
promoter	NULL
are	NULL
important	NULL
for	NULL
T	NULL
cell	NULL
activation-induced	NULL
FasL	NULL
expression	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Like	NULL
NF-AT	NULL
,	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
«	NULL
receptor	NULL
(	NULL
11	NULL
)	NULL
and	NULL
the	NULL
IL-2	NULL
genes	NULL
(	NULL
12	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
present	NULL
in	NULL
the	NULL
cytoplasm	NULL
as	NULL
two	NULL
major	NULL
precursor	NULL
forms	NULL
either	NULL
as	NULL
a	NULL
RelAp50	NULL
complex	NULL
with	NULL
the	NULL
inhibiting	NULL
I	NULL
«	NULL
B	NULL
or	NULL
as	NULL
a	NULL
heterodimeric	NULL
RelAp105	NULL
complex	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Release	NULL
of	NULL
the	NULL
RelA-p50	NULL
from	NULL
its	NULL
inhibitor	NULL
,	NULL
I	NULL
«	NULL
B	NULL
,	NULL
is	NULL
dependent	NULL
on	NULL
the	NULL
phosphorylation	NULL
of	NULL
IB	NULL
(	NULL
14	NULL
)	NULL
,	NULL
and	NULL
recently	NULL
,	NULL
the	NULL
kinases	NULL
that	NULL
phosphorylate	NULL
IxB	NULL
have	NULL
been	NULL
identified	NULL
(	NULL
15	NULL
)	NULL
.	NULL

NF-kB	NULL
is	NULL
then	NULL
translocated	NULL
into	NULL
the	NULL
nucleus	NULL
as	NULL
active	NULL
heterodimers	NULL
consisting	NULL
of	NULL
Rel	NULL
A	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
Rel	NULL
B	NULL
,	NULL
and	NULL
c-Rel	NULL
,	NULL
which	NULL
regulate	NULL
gene	NULL
expression	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
identified	NULL
a	NULL
role	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
another	NULL
transcription	NULL
factor	NULL
,	NULL
AP-1	NULL
,	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
stress-induced	NULL
FasL	NULL
expression	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
AP-1	NULL
regulate	NULL
FasL	NULL
expression	NULL
in	NULL
lymphocytes	NULL
activated	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Cell	NULL
Lines	NULL
and	NULL
Antibodies-Human	NULL
leukemic	NULL
Jurkat	NULL
cells	NULL
(	NULL
ATCC	NULL
)	NULL
and	NULL
Jurkat	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
SV40	NULL
large	NULL
T	NULL
antigen	NULL
were	NULL
used	NULL
in	NULL
this	NULL
study	NULL
.	NULL

The	NULL
T	NULL
cell	NULL
hybridoma	NULL
AL.1l	NULL
has	NULL
been	NULL
described	NULL
previously	NULL
(	NULL
2	NULL
)	NULL
.	NULL

All	NULL
cells	NULL
were	NULL
grown	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
,	NULL
and	NULL
100	NULL
units/ml	NULL
each	NULL
penicillin	NULL
and	NULL
streptomycin	NULL
(	NULL
complete	NULL
medium	NULL
)	NULL
.	NULL

Phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Sigma	NULL
,	NULL
and	NULL
ionomycin	NULL
was	NULL
purchased	NULL
from	NULL
Calbiochem	NULL
.	NULL

Mouse	NULL
anti-human	NULL
CD3	NULL
(	NULL
OKT3	NULL
)	NULL
antibody	NULL
and	NULL
hamster	NULL
anti-mouse	NULL
CD8e	NULL
(	NULL
145-2011	NULL
)	NULL
were	NULL
purified	NULL
from	NULL
culture	NULL
supernatants	NULL
by	NULL
protein	NULL
A	NULL
affinity	NULL
chromatography	NULL
.	NULL

Anti-p65	NULL
(	NULL
RelA	NULL
)	NULL
antibody	NULL
was	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
Apoptosis-All	NULL
experiments	NULL
were	NULL
performed	NULL
in	NULL
96-well	NULL
plates	NULL
and	NULL
in	NULL
triplicates	NULL
samples	NULL
,	NULL
with	NULL
cells	NULL
resuspended	NULL
at	NULL
0.5-1	NULL
%	NULL
10	NULL
%	NULL
/ml	NULL
in	NULL
complete	NULL
medium	NULL
.	NULL

For	NULL
T	NULL
cell	NULL
receptor	NULL
stimulation	NULL
,	NULL
96-well	NULL
plates	NULL
were	NULL
precoated	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
2C11	NULL
)	NULL
in	NULL
50	NULL
mM	NULL
Tris	NULL
,	NULL
pH	NULL
9.0	NULL
.	NULL

PMA	NULL
and	NULL
ionomycin	NULL
were	NULL
added	NULL
at	NULL
concentrations	NULL
of	NULL
50	NULL
ng/ml	NULL
and	NULL
0.5	NULL
ug/ml	NULL
,	NULL
respectively	NULL
.	NULL

Reverse	NULL
Transcription	NULL
(	NULL
RT	NULL
)	NULL
-PCR	NULL
for	NULL
FasL	NULL
Expression-The	NULL
expression	NULL
of	NULL
Fas-L	NULL
was	NULL
determined	NULL
by	NULL
RT	NULL
of	NULL
total	NULL
RNA	NULL
followed	NULL
by	NULL
reverse	NULL
PCR	NULL
analysis	NULL
(	NULL
RT-PCR	NULL
)	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cDNAs	NULL
were	NULL
synthesized	NULL
by	NULL
extension	NULL
of	NULL
dT	NULL
primers	NULL
with	NULL
200	NULL
units	NULL
of	NULL
SuperScript	NULL
II	NULL
reverse	NULL
transcriptase	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
in	NULL
a	NULL
mixture	NULL
containing	NULL
1	NULL
ug	NULL
of	NULL
total	NULL
RNA	NULL
digested	NULL
by	NULL
RNase-free	NULL
DNase	NULL
(	NULL
2	NULL
units/ug	NULL
of	NULL
RNA	NULL
)	NULL
(	NULL
Ambion	NULL
)	NULL
for	NULL
15	NULL
min	NULL
at	NULL
37	NULL
°C	NULL
.	NULL

PCR	NULL
of	NULL
the	NULL
cDNA	NULL
was	NULL
performed	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
50	NULL
ul	NULL
,	NULL
containing	NULL
all	NULL
four	NULL
dNTPs	NULL
,	NULL
2	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
2.5	NULL
units	NULL
of	NULL
AmpliTag	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
,	NULL
and	NULL
each	NULL
primer	NULL
at	NULL
0.2	NULL
uM	NULL
using	NULL
the	NULL
geneAmp	NULL
2400	NULL
PCR	NULL
system	NULL
(	NULL
Perkin-Elmer	NULL
)	NULL
.	NULL

Amplification	NULL
of	NULL
B-actin	NULL
served	NULL
as	NULL
control	NULL
for	NULL
sample	NULL
loading	NULL
and	NULL
integrity	NULL
.	NULL

The	NULL
following	NULL
primers	NULL
were	NULL
designed	NULL
to	NULL
discriminate	NULL
between	NULL
the	NULL
amplification	NULL
of	NULL
cDNA	NULL
(	NULL
low	NULL
size	NULL
PCR	NULL
products	NULL
)	NULL
and	NULL
contaminating	NULL
genomic	NULL
eDNA	NULL
(	NULL
high	NULL
size	NULL
PCR	NULL
products	NULL
)	NULL
:	NULL
This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
987	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
988	NULL
NF-kB	NULL
Regulates	NULL
TCR-mediated	NULL
FasL	NULL
Expression	NULL
hFasL	NULL
forward	NULL
:	NULL
TAAAACCGTTTGCTGGGGC	NULL
.	NULL

hFasL	NULL
reverse	NULL
:	NULL
CTCAGCTCCTTTTTTTCAGGGG	NULL
.	NULL

B-Actin	NULL
forward	NULL
:	NULL
TGACGGGGTCACCCACACTGTGCCCATCTA	NULL
.	NULL

B-Actin	NULL
reverse	NULL
:	NULL
CTAGAAGCATTTGCGGTGGACGATGGAGGG	NULL
.	NULL

Expression	NULL
Vectors	NULL
and	NULL
Transient	NULL
Transfections-Cloning	NULL
of	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
promoter	NULL
and	NULL
generation	NULL
of	NULL
the	NULL
truncated	NULL
version	NULL
was	NULL
described	NULL
before	NULL
(	NULL
16	NULL
)	NULL
.	NULL

A	NULL
1.2-	NULL
and	NULL
a	NULL
0.9-kb	NULL
fragment	NULL
of	NULL
the	NULL
hFasL	NULL
promoter	NULL
were	NULL
subsequently	NULL
used	NULL
in	NULL
the	NULL
experiments	NULL
described	NULL
here	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
containing	NULL
stably	NULL
transfected	NULL
SV40	NULL
large	NULL
T	NULL
antigen	NULL
were	NULL
electroporated	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
1.5-2	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
serum-free	NULL
RPMI	NULL
1640	NULL
medium	NULL
,	NULL
resuspended	NULL
in	NULL
500	NULL
ul	NULL
of	NULL
the	NULL
same	NULL
medium	NULL
,	NULL
and	NULL
transferred	NULL
to	NULL
4-mm	NULL
gap	NULL
electroporation	NULL
cuvettes	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

20-60	NULL
pug	NULL
of	NULL
FasL	NULL
reporter	NULL
alone	NULL
or	NULL
with	NULL
Sra	NULL
p65	NULL
,	NULL
IxB	NULL
,	NULL
IxBaM	NULL
,	NULL
or	NULL
DN	NULL
MEKK	NULL
expression	NULL
vectors	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
were	NULL
added	NULL
to	NULL
the	NULL
cells	NULL
and	NULL
mixed	NULL
well	NULL
.	NULL

Electroporation	NULL
was	NULL
carried	NULL
out	NULL
at	NULL
250	NULL
V	NULL
and	NULL
960	NULL
microfarads	NULL
in	NULL
a	NULL
Bio-Rad	NULL
Gene	NULL
Pulse	NULL
IL	NULL
.	NULL

Luciferase	NULL
Assays-Briefly	NULL
,	NULL
different	NULL
hFasL	NULL
promoter	NULL
constructs	NULL
were	NULL
transfected	NULL
with	NULL
or	NULL
without	NULL
co-expression	NULL
vectors	NULL
.	NULL

pCMV	NULL
B-galac-tosidase	NULL
was	NULL
used	NULL
to	NULL
normalize	NULL
the	NULL
transfection	NULL
efficiencies	NULL
in	NULL
the	NULL
various	NULL
co-transfections	NULL
.	NULL

Forty	NULL
h	NULL
post-transfection	NULL
,	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
and	NULL
incubated	NULL
for	NULL
another	NULL
12-18	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
PBS	NULL
,	NULL
and	NULL
lysed	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
the	NULL
lysis	NULL
buffer	NULL
.	NULL

Cell	NULL
debris	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
used	NULL
in	NULL
the	NULL
luciferase	NULL
assay	NULL
using	NULL
a	NULL
Monolight	NULL
2010	NULL
luminometer	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Electromobility	NULL
Shift	NULL
Assays-DNA	NULL
binding	NULL
reactions	NULL
were	NULL
carried	NULL
out	NULL
for	NULL
20	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
a	NULL
buffer	NULL
containing	NULL
50	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.8	NULL
,	NULL
20	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
20	NULL
mM	NULL
spermidine	NULL
,	NULL
500	NULL
ug/ml	NULL
bovine	NULL
serum	NULL
albumin	NULL
,	NULL
10	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
75	NULL
%	NULL
glycerol	NULL
,	NULL
and	NULL
10°	NULL
counts/min	NULL
labeled	NULL
probe	NULL
.	NULL

The	NULL
probes	NULL
used	NULL
were	NULL
double-stranded	NULL
synthetic	NULL
oligonucleotides	NULL
(	NULL
Retrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
consisting	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
from	NULL
the	NULL
human	NULL
FasL	NULL
promoter	NULL
,	NULL
5'-AAGCCTGGGCAACATAGAAAGTCCCCATCTGTA-CAAAAA-3	NULL
'	NULL
,	NULL
and	NULL
the	NULL
consensus	NULL
NF-KB	NULL
oligonucleotide	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Inc.	NULL
Each	NULL
strand	NULL
was	NULL
labeled	NULL
separately	NULL
with	NULL
T4	NULL
polynu-cleotide	NULL
kinase	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
and	NULL
(	NULL
5000	NULL
Ci/mmol	NULL
)	NULL
,	NULL
and	NULL
the	NULL
strands	NULL
were	NULL
then	NULL
slowly	NULL
allowed	NULL
to	NULL
reanneal	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
analyzed	NULL
on	NULL
a	NULL
4	NULL
%	NULL
nondenaturing	NULL
acrylamide	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
Tris-buffered	NULL
EDTA	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
were	NULL
made	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
contained	NULL
5-10	NULL
ug	NULL
of	NULL
nuclear	NULL
extract	NULL
,	NULL
*°P-labeled	NULL
probe	NULL
(	NULL
25,000	NULL
cpm	NULL
)	NULL
,	NULL
and	NULL
2	NULL
pug	NULL
of	NULL
poly	NULL
(	NULL
dI	NULL
:	NULL
dC	NULL
)	NULL
in	NULL
the	NULL
binding	NULL
buffer	NULL
.	NULL

RESULTS	NULL
Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
Diminishes	NULL
FasL	NULL
Expression	NULL
and	NULL
T	NULL
Cell	NULL
Receptor-mediated	NULL
Apoptosis-It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
required	NULL
for	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
antioxidants	NULL
inhibit	NULL
activation-induced	NULL
cell	NULL
death	NULL
by	NULL
blocking	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
and	NULL
thereby	NULL
blocking	NULL
FasL	NULL
expression	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Similarly	NULL
,	NULL
we	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
required	NULL
for	NULL
stress-induced	NULL
FasL	NULL
expression	NULL
and	NULL
apoptosis	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
previous	NULL
studies	NULL
by	NULL
ourselves	NULL
and	NULL
others	NULL
have	NULL
suggested	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
can	NULL
act	NULL
as	NULL
an	NULL
inhibitor	NULL
of	NULL
apoptosis	NULL
induced	NULL
by	NULL
TNF	NULL
(	NULL
21-24	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
sought	NULL
to	NULL
determine	NULL
whether	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
can	NULL
inhibit	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
examine	NULL
this	NULL
possibility	NULL
,	NULL
we	NULL
employed	NULL
a	NULL
recently	NULL
described	NULL
inhibitor	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
composed	NULL
of	NULL
a	NULL
cell-permeable	NULL
peptide	NULL
carrying	NULL
the	NULL
nuclear	NULL
localization	NULL
signal	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
subunit	NULL
(	NULL
25	NULL
)	NULL
.	NULL

This	NULL
peptide	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
specifically	NULL
inhibit	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
complexes	NULL
(	NULL
26	NULL
)	NULL
.	NULL

We	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
NF-B	NULL
inhibitory	NULL
peptide	NULL
or	NULL
a	NULL
control	NULL
peptide	NULL
in	NULL
preventing	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
a	NULL
T	NULL
cell	NULL
hybridoma	NULL
.	NULL

The	NULL
T	NULL
cell	NULL
hybridoma	NULL
A1.1	NULL
undergoes	NULL
expression	NULL
of	NULL
FasL	NULL
and	NULL
apoptosis	NULL
when	NULL
cross-linked	NULL
with	NULL
anti-T	NULL
cell	NULL
receptor	NULL
antibodies	NULL
(	NULL
1	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
a	NULL
significant	NULL
decrease	NULL
in	NULL
apoptosis	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
inhibitory	NULL
peptide	NULL
and	NULL
not	NULL
the	NULL
control	NULL
peptide	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

We	NULL
then	NULL
assessed	NULL
FasL	NULL
expression	NULL
by	NULL
semi-quantitative	NULL
RT-PCR	NULL
in	NULL
these	NULL
cells	NULL
and	NULL
observed	NULL
a	NULL
corresponding	NULL
inhibition	NULL
in	NULL
the	NULL
level	NULL
of	NULL
FasL	NULL
mRNA	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

To-gether	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
NF-kB	NULL
may	NULL
be	NULL
an	NULL
important	NULL
mediator	NULL
of	NULL
activation-induced	NULL
FasL	NULL
expression	NULL
and	NULL
subsequent	NULL
cell	NULL
death	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
Promoter	NULL
for	NULL
TCR-medi-	NULL
A	NULL
-so	NULL
40	NULL
4	NULL
w	NULL
I	NULL
;	NULL
30	NULL
a	NULL
«	NULL
20	NULL
[	NULL
-l	NULL
$	NULL
&	NULL
,	NULL
10	NULL
6	NULL
0	NULL
E0	NULL
2°	NULL
§	NULL
&	NULL
A	NULL
:	NULL
li	NULL
=-IC	NULL
3	NULL
;	NULL
peptide	NULL
(	NULL
g/ml	NULL
)	NULL
B	NULL
3	NULL
Iss	NULL
©	NULL
C	NULL
9	NULL
po	NULL
€	NULL
cl	NULL
-R	NULL
a	NULL
£	NULL
cee	NULL
A	NULL
Ce	NULL
=	NULL
O4	NULL
-	NULL
4	NULL
Anti-CD3	NULL
FasL	NULL
B-Actin	NULL
pas	NULL
~I	NULL
fold	NULL
increase	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Inhibition	NULL
of	NULL
NFB	NULL
blocks	NULL
activation-induced	NULL
cell	NULL
death	NULL
and	NULL
FasL	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
AL.1	NULL
T	NULL
hybridoma	NULL
cells	NULL
were	NULL
activated	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
«	NULL
B	NULL
inhibitory	NULL
peptide	NULL
(	NULL
@	NULL
)	NULL
or	NULL
the	NULL
control	NULL
peptide	NULL
(	NULL
0	NULL
)	NULL
for	NULL
12-16	NULL
h	NULL
,	NULL
and	NULL
cell	NULL
death	NULL
was	NULL
assessed	NULL
by	NULL
propidium	NULL
iodide	NULL
uptake	NULL
on	NULL
FACS	NULL
.	NULL

Apoptotic	NULL
cells	NULL
were	NULL
also	NULL
analyzed	NULL
by	NULL
staining	NULL
with	NULL
acridine	NULL
orange	NULL
and	NULL
ethidium	NULL
bromide	NULL
and	NULL
examining	NULL
the	NULL
morphology	NULL
by	NULL
fluorescent	NULL
microscopy	NULL
.	NULL

B	NULL
,	NULL
RT-PCR	NULL
analysis	NULL
of	NULL
total	NULL
mRNA	NULL
isolated	NULL
from	NULL
A1.1	NULL
cells	NULL
activated	NULL
as	NULL
described	NULL
above	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
«	NULL
B	NULL
inhibitory	NULL
peptide	NULL
or	NULL
the	NULL
control	NULL
peptide	NULL
.	NULL

ated	NULL
Signaling	NULL
Events-Activation-induced	NULL
cell	NULL
death	NULL
is	NULL
mediated	NULL
by	NULL
regulation	NULL
of	NULL
Fas/FasL	NULL
expression	NULL
.	NULL

T	NULL
cell	NULL
receptor	NULL
cross-linking	NULL
and	NULL
pharmacologic	NULL
agents	NULL
mimicking	NULL
these	NULL
signals	NULL
also	NULL
induce	NULL
FasL	NULL
expression	NULL
(	NULL
27	NULL
)	NULL
.	NULL

There	NULL
are	NULL
potential	NULL
binding	NULL
sites	NULL
for	NULL
several	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
1.2-kb	NULL
promoter	NULL
region	NULL
of	NULL
Fas	NULL
ligand	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

To	NULL
understand	NULL
the	NULL
results	NULL
obtained	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
and	NULL
to	NULL
dissect	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
T	NULL
cell	NULL
receptor-mediated	NULL
FasL	NULL
expression	NULL
,	NULL
we	NULL
used	NULL
a	NULL
1.2-kb	NULL
FasL	NULL
promoter	NULL
(	NULL
16	NULL
)	NULL
and	NULL
examined	NULL
whether	NULL
this	NULL
reporter	NULL
is	NULL
activated	NULL
upon	NULL
TCR	NULL
ligation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
promoter	NULL
was	NULL
activated	NULL
upon	NULL
cross-linking	NULL
of	NULL
the	NULL
TCR	NULL
receptor	NULL
with	NULL
anti-CD3	NULL
antibody	NULL
as	NULL
well	NULL
as	NULL
upon	NULL
stimulation	NULL
with	NULL
the	NULL
pharmacologic	NULL
agents	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
reported	NULL
in	NULL
studies	NULL
using	NULL
a	NULL
486-bp	NULL
FasL	NULL
reporter	NULL
construct	NULL
(	NULL
10	NULL
)	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
regulatory	NULL
domains	NULL
that	NULL
mediate	NULL
this	NULL
inducible	NULL
transcription	NULL
of	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
promoter	NULL
,	NULL
we	NULL
then	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
a	NULL
0.9-kb	NULL
FasL	NULL
reporter	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
that	NULL
has	NULL
its	NULL
5	NULL
'	NULL
enhancer	NULL
truncated	NULL
.	NULL

In	NULL
the	NULL
experiment	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
when	NULL
T	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
FasL	NULL
reporter	NULL
activity	NULL
of	NULL
the	NULL
0.9-kb	NULL
promoter	NULL
was	NULL
significantly	NULL
reduced	NULL
versus	NULL
that	NULL
of	NULL
the	NULL
1.2-kb	NULL
promoter	NULL
.	NULL

T	NULL
Cell	NULL
Activation	NULL
Induces	NULL
Binding	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
Its	NULL
Cognate	NULL
DNA-To	NULL
further	NULL
examine	NULL
the	NULL
possible	NULL
role	NULL
of	NULL
NF-KB	NULL
in	NULL
AICD	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
activation-dependent	NULL
characteristics	NULL
of	NULL
a	NULL
NF-	NULL
«	NULL
B	NULL
reporter	NULL
construct	NULL
carrying	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
consensus	NULL
«	NULL
B	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
NF-kB	NULL
Regulates	NULL
TCR-mediated	NULL
FasL	NULL
Expression	NULL
989	NULL
A	NULL
Human	NULL
Fas	NULL
Ligand	NULL
Promoter	NULL
NEacH	NULL
¥	NULL
1.2	NULL
kb	NULL
NE-AT	NULL
_	NULL
NEAT	NULL
___	NULL
Bm	NULL
___	NULL
tx	NULL
]	NULL
0.9	NULL
kh	NULL
B	NULL
C	NULL
307	NULL
E	NULL
10007	NULL
Z	NULL
s	NULL
&	NULL
control	NULL
5	NULL
``	NULL
>	NULL
m	NULL
P+	NULL
€	NULL
Z	NULL
soo	NULL
a	NULL
1	NULL
Ld	NULL
3	NULL
20	NULL
j	NULL
;	NULL
a	NULL
E	NULL
600	NULL
7	NULL
:	NULL
3	NULL
42	NULL
<	NULL
&	NULL
3	NULL
2	NULL
a00-200	NULL
3	NULL
y	NULL
S	NULL
a	NULL
u	NULL
L=	NULL
L	NULL
3	NULL
3	NULL
E	NULL
=	NULL
2007	NULL
T	NULL
0	NULL
~	NULL
0~	NULL
%	NULL
1.2kb	NULL
__	NULL
09kb	NULL
control	NULL
anti-CD3	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

T	NULL
cell	NULL
activation	NULL
induces	NULL
the	NULL
FasL	NULL
reporter	NULL
.	NULL

A	NULL
,	NULL
schematic	NULL
representation	NULL
of	NULL
the	NULL
identified	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
in	NULL
the	NULL
FasL	NULL
promoter	NULL
.	NULL

B	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
luciferase	NULL
reporter	NULL
construct	NULL
containing	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
reporter	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
anti-TCR	NULL
antibodies	NULL
(	NULL
OKT3	NULL
)	NULL
or	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
,	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
determined	NULL
after	NULL
approximately	NULL
16	NULL
h.	NULL
C	NULL
,	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
luciferase	NULL
reporter	NULL
constructs	NULL
containing	NULL
1.2	NULL
or	NULL
0.9	NULL
kb	NULL
of	NULL
the	NULL
FasL	NULL
reporter	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
,	NULL
and	NULL
ionomycin	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
determined	NULL
after	NULL
16	NULL
h.	NULL
motif	NULL
(	NULL
28	NULL
)	NULL
and	NULL
found	NULL
that	NULL
NF-B	NULL
is	NULL
activated	NULL
upon	NULL
stimulation	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
.	NULL

A	NULL
mutation	NULL
in	NULL
the	NULL
site	NULL
abrogated	NULL
this	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
the	NULL
distal	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
binds	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
proteins	NULL
from	NULL
nuclear	NULL
extracts	NULL
treated	NULL
with	NULL
the	NULL
DNA-damaging	NULL
agent	NULL
,	NULL
etoposide	NULL
(	NULL
16	NULL
)	NULL
.	NULL

After	NULL
treatment	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
we	NULL
then	NULL
examined	NULL
nuclear	NULL
extracts	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
activity	NULL
by	NULL
an	NULL
electromobility	NULL
shift	NULL
assay	NULL
,	NULL
using	NULL
the	NULL
distal	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
from	NULL
the	NULL
FasL	NULL
promoter	NULL
(	NULL
16	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
T	NULL
cell	NULL
activation	NULL
induced	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
in	NULL
an	NULL
activation-dependent	NULL
manner	NULL
.	NULL

The	NULL
binding	NULL
to	NULL
this	NULL
site	NULL
was	NULL
competed	NULL
off	NULL
by	NULL
the	NULL
wild	NULL
type	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
motif	NULL
(	NULL
GGGGACTTTCCC	NULL
)	NULL
(	NULL
29	NULL
)	NULL
and	NULL
by	NULL
an	NULL
anti-p65	NULL
antibody	NULL
(	NULL
30	NULL
)	NULL
but	NULL
not	NULL
by	NULL
control	NULL
serum	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
complex	NULL
formation	NULL
by	NULL
anti-p65	NULL
antibody	NULL
also	NULL
suggests	NULL
that	NULL
p65	NULL
is	NULL
part	NULL
of	NULL
the	NULL
complex	NULL
induced	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
treatment	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-kB	NULL
Prevents	NULL
FasL	NULL
Reporter	NULL
Activity-Ear-lier	NULL
studies	NULL
using	NULL
chemical	NULL
activators	NULL
of	NULL
cAMP	NULL
signaling	NULL
(	NULL
81	NULL
)	NULL
and	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
have	NULL
suggested	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
could	NULL
be	NULL
involved	NULL
in	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
20	NULL
,	NULL
32	NULL
)	NULL
.	NULL

The	NULL
experiments	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
suggested	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
required	NULL
for	NULL
optimal	NULL
activation-induced	NULL
cell	NULL
death	NULL
and	NULL
FasL	NULL
expression	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
the	NULL
possibility	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
directly	NULL
regulates	NULL
T	NULL
cell	NULL
activation-mediated	NULL
FasL	NULL
transcription	NULL
.	NULL

Based	NULL
on	NULL
the	NULL
dependence	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
on	NULL
the	NULL
effective	NULL
degradation	NULL
of	NULL
IxB	NULL
,	NULL
we	NULL
first	NULL
took	NULL
the	NULL
approach	NULL
of	NULL
inhibiting	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
using	NULL
IB	NULL
or	NULL
a	NULL
nondegradable	NULL
mutant	NULL
IxBaM	NULL
(	NULL
21	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
co-transfected	NULL
Jurkat	NULL
cells	NULL
with	NULL
the	NULL
FasL	NULL
reporter	NULL
construct	NULL
together	NULL
with	NULL
either	NULL
wild	NULL
type	NULL
IxB	NULL
or	NULL
the	NULL
nondegradable	NULL
mutant	NULL
IxBaM	NULL
(	NULL
21	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
either	NULL
form	NULL
of	NULL
IB	NULL
effectively	NULL
blocked	NULL
the	NULL
basal	NULL
activity	NULL
as	NULL
well	NULL
as	NULL
activation	NULL
of	NULL
the	NULL
FasL	NULL
promoter	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
.	NULL

A	NULL
_	NULL
600	NULL
``	NULL
3	NULL
Fs	NULL
1	NULL
§	NULL
control	NULL
_	NULL
500	NULL
m	NULL
P+	NULL
2	NULL
5	NULL
400	NULL
o	NULL
#	NULL
E	NULL
300	NULL
€	NULL
1	NULL
3	NULL
200	NULL
B	NULL
a	NULL
100	NULL
&	NULL
t	NULL
0	NULL
2x	NULL
kB	NULL
_	NULL
2x	NULL
xB	NULL
(	NULL
WT	NULL
)	NULL
_	NULL
(	NULL
mut	NULL
)	NULL
2020+	NULL
anti	NULL
p6S	NULL
-	NULL
4	NULL
.	NULL

_	NULL
.	NULL

__	NULL
control	NULL
serum	NULL
Time	NULL
course	NULL
_	NULL
0	NULL
_	NULL
05	NULL
1	NULL
2	NULL
4	NULL
8	NULL
-	NULL
-	NULL
>	NULL
-	NULL
<	NULL
+	NULL
_	NULL
consensus	NULL
NF-KB	NULL
oligo	NULL
'LMAAMM	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

T	NULL
cell	NULL
activation	NULL
induces	NULL
the	NULL
transcription	NULL
factor	NULL
NF-iB	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
(	NULL
WT	NULL
)	NULL
kB	NULL
reporter	NULL
construct	NULL
containing	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
consensus	NULL
«	NULL
B	NULL
motif	NULL
or	NULL
a	NULL
construct	NULL
containing	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
as	NULL
shown	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
,	NULL
and	NULL
ionomycin	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
determined	NULL
after	NULL
12-16	NULL
h.	NULL
B	NULL
,	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
site	NULL
in	NULL
the	NULL
FasL	NULL
promoter	NULL
is	NULL
required	NULL
for	NULL
T	NULL
cell	NULL
receptor-mediated	NULL
activation	NULL
.	NULL

Nuclear	NULL
extracts	NULL
made	NULL
from	NULL
T	NULL
cells	NULL
activated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
were	NULL
employed	NULL
in	NULL
an	NULL
electromobility	NULL
shift	NULL
assays	NULL
with	NULL
an	NULL
oligonucleotide	NULL
corresponding	NULL
to	NULL
the	NULL
putative	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
sequence	NULL
in	NULL
the	NULL
FasL	NULL
promoter	NULL
(	NULL
GGGGACTTTCT	NULL
)	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
identified	NULL
an	NULL
NF-	NULL
«	NULL
B	NULL
responsive	NULL
element	NULL
in	NULL
the	NULL
FasL	NULL
promoter	NULL
essential	NULL
for	NULL
stress-induced	NULL
promoter	NULL
activity	NULL
(	NULL
16	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
importance	NULL
of	NULL
this	NULL
NF-kB	NULL
site	NULL
in	NULL
activation-induced	NULL
FasL	NULL
promoter	NULL
activation	NULL
,	NULL
we	NULL
used	NULL
a	NULL
reporter	NULL
construct	NULL
in	NULL
which	NULL
this	NULL
site	NULL
was	NULL
mutated	NULL
(	NULL
16	NULL
)	NULL
and	NULL
tested	NULL
for	NULL
its	NULL
ability	NULL
to	NULL
be	NULL
induced	NULL
upon	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
mutating	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
had	NULL
a	NULL
profound	NULL
effect	NULL
on	NULL
T	NULL
cell	NULL
activation-mediated	NULL
FasL	NULL
expression	NULL
,	NULL
further	NULL
supporting	NULL
the	NULL
idea	NULL
that	NULL
NF-kB	NULL
is	NULL
required	NULL
for	NULL
optimal	NULL
activation	NULL
of	NULL
the	NULL
FasL	NULL
promoter	NULL
.	NULL

p65	NULL
RelA	NULL
Increases	NULL
FasL	NULL
Reporter	NULL
Activity	NULL
upon	NULL
T	NULL
Cell	NULL
Acti-vation-The	NULL
ability	NULL
of	NULL
the	NULL
various	NULL
Rel-related	NULL
proteins	NULL
to	NULL
recognize	NULL
DNA	NULL
sequence	NULL
elements	NULL
through	NULL
either	NULL
homo-	NULL
or	NULL
het-erodimer	NULL
formation	NULL
may	NULL
be	NULL
a	NULL
mechanism	NULL
whereby	NULL
selective	NULL
functional	NULL
regulation	NULL
by	NULL
this	NULL
family	NULL
of	NULL
proteins	NULL
is	NULL
achieved	NULL
.	NULL

It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
the	NULL
p65	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
can	NULL
act	NULL
as	NULL
a	NULL
transcriptional	NULL
activator	NULL
(	NULL
83	NULL
)	NULL
.	NULL

Co-expression	NULL
of	NULL
p65	NULL
(	NULL
Rel	NULL
A	NULL
)	NULL
with	NULL
the	NULL
FasL	NULL
reporter	NULL
induced	NULL
constitutive	NULL
FasL	NULL
reporter	NULL
activity	NULL
and	NULL
enhanced	NULL
the	NULL
ability	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
to	NULL
drive	NULL
this	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

54	NULL
)	NULL
.	NULL

The	NULL
NF-kB	NULL
mutation	NULL
also	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
this	NULL
promoter	NULL
to	NULL
be	NULL
induced	NULL
by	NULL
co-expression	NULL
of	NULL
the	NULL
p65	NULL
subunit	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Transient	NULL
overexpression	NULL
of	NULL
p65	NULL
was	NULL
sufficient	NULL
to	NULL
induce	NULL
expression	NULL
of	NULL
the	NULL
endogenous	NULL
Fas	NULL
ligand	NULL
gene	NULL
in	NULL
Jurkat	NULL
cells	NULL
as	NULL
assessed	NULL
by	NULL
semi-quantitative	NULL
PCR	NULL
(	NULL
Fig	NULL
.	NULL

5C	NULL
)	NULL
.	NULL

These	NULL
data	NULL
support	NULL
a	NULL
role	NULL
for	NULL
NF-B	NULL
in	NULL
driving	NULL
the	NULL
FasL	NULL
promoter	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

AP-1	NULL
Is	NULL
Not	NULL
Critical	NULL
for	NULL
TCR-mediated	NULL
FasL	NULL
Promoter	NULL
Acti-vation-Recently	NULL
,	NULL
Latinis	NULL
et	NULL
al	NULL
.	NULL

(	NULL
10	NULL
)	NULL
showed	NULL
that	NULL
NF-AT	NULL
is	NULL
an	NULL
important	NULL
transcription	NULL
factor	NULL
required	NULL
for	NULL
activation-induced	NULL
FasL	NULL
expression	NULL
.	NULL

Similarly	NULL
,	NULL
we	NULL
identified	NULL
AP-1	NULL
and	NULL
NF-KB	NULL
sites	NULL
required	NULL
for	NULL
stress-induced	NULL
FasL	NULL
expression	NULL
(	NULL
16	NULL
)	NULL
.	NULL

T	NULL
cell	NULL
receptor	NULL
ligation	NULL
activates	NULL
the	NULL
early	NULL
genes	NULL
fos	NULL
and	NULL
jun	NULL
that	NULL
het-erodimerize	NULL
and	NULL
bind	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
to	NULL
regulate	NULL
IL-2	NULL
and	NULL
other	NULL
cytokine	NULL
gene	NULL
transcription	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Phosphorylation	NULL
of	NULL
c-Jun	NULL
by	NULL
c-Jun	NULL
N-terminal	NULL
kinases	NULL
(	NULL
JNK/SAPK	NULL
)	NULL
is	NULL
required	NULL
for	NULL
AP-1-de-pendent	NULL
promoter	NULL
activity	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Inhibiting	NULL
c-Jun	NULL
phosphoryla-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
990	NULL
NF-kB	NULL
Regulates	NULL
TCR-mediated	NULL
FasL	NULL
Expression	NULL
A	NULL
300	NULL
&	NULL
G	NULL
control	NULL
<	NULL
H	NULL
P+	NULL
]	NULL
<	NULL
2	NULL
w	NULL
Aa	NULL
-	NULL
2004	NULL
=	NULL
=	NULL
d	NULL
w	NULL
fad	NULL
2	NULL
3	NULL
100-9	NULL
's	NULL
weg	NULL
2	NULL
0	NULL
hFasL	NULL
Pr	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
IxB	NULL
WT	NULL
i	NULL
+	NULL
+	NULL
=	NULL
=	NULL
Ix	NULL
Ba	NULL
M	NULL
=	NULL
=	NULL
~	NULL
+	NULL
+	NULL
B	NULL
&	NULL
10007	NULL
§	NULL
control	NULL
=	NULL
6	NULL
P+I	NULL
=	NULL
Z	NULL
-	NULL
$	NULL
007	NULL
43	NULL
m	NULL
=	NULL
600	NULL
y	NULL
w	NULL
x	NULL
)	NULL
g	NULL
400	NULL
7	NULL
1	NULL
R-o	NULL
200	NULL
7	NULL
>	NULL
``	NULL
os	NULL
3	NULL
2	NULL
0	NULL
WT	NULL
mutant	NULL
wild	NULL
type	NULL
mutant	NULL
NF-KB	NULL
GGGGACTTTCT	NULL
GGCGACTTTCT	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
required	NULL
for	NULL
activation-induced	NULL
FasL	NULL
promoter	NULL
activity	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
reporter	NULL
construct	NULL
plus	NULL
or	NULL
minus	NULL
expression	NULL
constructs	NULL
for	NULL
IxB	NULL
or	NULL
IkBaM	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
P+2	NULL
)	NULL
,	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
determined	NULL
after	NULL
12-16	NULL
h.	NULL
B	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
wild	NULL
type	NULL
FasL	NULL
reporter	NULL
construct	NULL
or	NULL
a	NULL
construct	NULL
containing	NULL
the	NULL
mutation	NULL
in	NULL
the	NULL
NF-kB	NULL
site	NULL
as	NULL
shown	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
determined	NULL
after	NULL
12-16	NULL
h.	NULL
WT	NULL
,	NULL
wild	NULL
type	NULL
.	NULL

tion	NULL
by	NULL
a	NULL
DN-MEKK	NULL
(	NULL
KA432M	NULL
)	NULL
also	NULL
down-regulates	NULL
AP-1-de-pendent	NULL
reporter	NULL
activity	NULL
(	NULL
35	NULL
)	NULL
.	NULL

To	NULL
study	NULL
the	NULL
effects	NULL
of	NULL
DN-MEKK	NULL
on	NULL
FasL	NULL
reporter	NULL
activity	NULL
,	NULL
we	NULL
cotransfected	NULL
the	NULL
FasL	NULL
reporter	NULL
with	NULL
a	NULL
DN-MEKK	NULL
expression	NULL
vector	NULL
and	NULL
observed	NULL
that	NULL
DN-MEKK	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
TCR-mediated	NULL
FasL	NULL
reporter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

64	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
and	NULL
as	NULL
shown	NULL
earlier	NULL
(	NULL
16	NULL
)	NULL
,	NULL
DN-MEKK	NULL
inhibited	NULL
stress-induced	NULL
FasL	NULL
reporter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

We	NULL
then	NULL
investigated	NULL
whether	NULL
the	NULL
distal	NULL
AP-1	NULL
binding	NULL
site	NULL
(	NULL
16	NULL
)	NULL
was	NULL
required	NULL
for	NULL
TCR-mediated	NULL
FasL	NULL
transcription	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6B	NULL
,	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
AP-1	NULL
site	NULL
did	NULL
not	NULL
alter	NULL
FasL	NULL
reporter	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
T	NULL
cell	NULL
receptor	NULL
signaling	NULL
,	NULL
thus	NULL
suggesting	NULL
the	NULL
involvement	NULL
of	NULL
a	NULL
different	NULL
signaling	NULL
mechanism	NULL
.	NULL

A	NULL
2000	NULL
-	NULL
B	NULL
{	NULL
§	NULL
control	NULL
1200	NULL
&	NULL
control	NULL
g	NULL
N	NULL
P+	NULL
!	NULL

&	NULL
N	NULL
p65	NULL
cl	NULL
7	NULL
1000	NULL
&	NULL
w	NULL
5	NULL
5	NULL
800	NULL
PI	NULL
©	NULL
3	NULL
1000	NULL
H	NULL
E	NULL
€	NULL
600	NULL
4	NULL
3	NULL
400	NULL
3	NULL
a	NULL
$	NULL
s	NULL
200	NULL
o	NULL
-	NULL
0	NULL
hFasL	NULL
Pr	NULL
+o	NULL
+	NULL
WPF	NULL
:	NULL
mat	NULL
p6S	NULL
=	NULL
+	NULL
C	NULL
p6S	NULL
(	NULL
ReIA	NULL
)	NULL
|	NULL
-	NULL
-	NULL
+	NULL
+	NULL
P+I	NULL
wok	NULL
s	NULL
|	NULL
--	NULL
~-	NULL
-I	NULL
Fig	NULL
.	NULL

5.	NULL
p65	NULL
Rel	NULL
enhanced	NULL
activation-induced	NULL
FasL	NULL
promoter	NULL
activity	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
reporter	NULL
construct	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
for	NULL
p65	NULL
Rel	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
,	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
determined	NULL
after	NULL
12-16	NULL
h.	NULL
B	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
reporter	NULL
construct	NULL
or	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
reporter	NULL
that	NULL
contains	NULL
the	NULL
NF-KB	NULL
site	NULL
mutation	NULL
(	NULL
mut	NULL
)	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
an	NULL
expression	NULL
vector	NULL
for	NULL
p65	NULL
Rel	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
determined	NULL
after	NULL
12-16	NULL
h.	NULL
WT	NULL
,	NULL
wild	NULL
type	NULL
.	NULL

C	NULL
,	NULL
p65	NULL
(	NULL
RelA	NULL
)	NULL
was	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

Forty	NULL
eight	NULL
h	NULL
later	NULL
,	NULL
cells	NULL
were	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
activated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
for	NULL
4	NULL
h	NULL
and	NULL
harvested	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
isolated	NULL
,	NULL
and	NULL
a	NULL
semi-quantitative	NULL
PCR	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Experimental	NULL
Procedures	NULL
.	NULL
``	NULL

We	NULL
have	NULL
previously	NULL
observed	NULL
that	NULL
this	NULL
mutation	NULL
abolishes	NULL
the	NULL
response	NULL
of	NULL
the	NULL
promoter	NULL
to	NULL
DNA-damaging	NULL
agents	NULL
(	NULL
16	NULL
)	NULL
.	NULL

DISCUSSION	NULL
TCR	NULL
engagement	NULL
and	NULL
activation	NULL
often	NULL
leads	NULL
to	NULL
growth	NULL
and	NULL
differentiation	NULL
as	NULL
well	NULL
as	NULL
apoptosis	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Some	NULL
of	NULL
the	NULL
proximal	NULL
signaling	NULL
events	NULL
lead	NULL
to	NULL
activation	NULL
of	NULL
AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
NF-AT	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
(	NULL
9	NULL
)	NULL
,	NULL
which	NULL
are	NULL
known	NULL
to	NULL
activate	NULL
cytokine	NULL
gene	NULL
transcription	NULL
.	NULL

A	NULL
substantial	NULL
amount	NULL
of	NULL
work	NULL
in	NULL
the	NULL
past	NULL
several	NULL
years	NULL
has	NULL
helped	NULL
our	NULL
understanding	NULL
of	NULL
this	NULL
complex	NULL
cytokine	NULL
gene	NULL
regulation	NULL
.	NULL

There	NULL
is	NULL
also	NULL
evidence	NULL
that	NULL
transcription	NULL
can	NULL
play	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
mechanisms	NULL
involved	NULL
in	NULL
some	NULL
forms	NULL
of	NULL
apoptosis	NULL
,	NULL
such	NULL
as	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Activation-induced	NULL
cell	NULL
death	NULL
is	NULL
primarily	NULL
mediated	NULL
by	NULL
Fas/	NULL
FasL	NULL
in	NULL
mature	NULL
T	NULL
lymphocytes	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

Previously	NULL
,	NULL
Latinis	NULL
et	NULL
al	NULL
.	NULL

(	NULL
10	NULL
)	NULL
showed	NULL
that	NULL
NF-AT	NULL
regulates	NULL
activation-induced	NULL
FasL	NULL
promoter	NULL
activity	NULL
.	NULL

Similarly	NULL
,	NULL
we	NULL
showed	NULL
recently	NULL
that	NULL
the	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
regulate	NULL
DNA	NULL
damage	NULL
and	NULL
other	NULL
stress-induced	NULL
FasL	NULL
expression	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
have	NULL
provided	NULL
evidence	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
also	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
T	NULL
cell	NULL
activation-mediated	NULL
FasL	NULL
expression	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
reporter	NULL
was	NULL
dependent	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
that	NULL
inhibiting	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
into	NULL
the	NULL
nucleus	NULL
also	NULL
inhibited	NULL
FasL	NULL
expression	NULL
and	NULL
apoptosis	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
was	NULL
originally	NULL
identified	NULL
as	NULL
a	NULL
constitutively	NULL
expressed	NULL
protein	NULL
that	NULL
can	NULL
form	NULL
a	NULL
complex	NULL
with	NULL
a	NULL
10-bp	NULL
site	NULL
in	NULL
the	NULL
im-munoglobulin	NULL
x	NULL
light	NULL
chain	NULL
enhancer	NULL
(	NULL
36	NULL
)	NULL
.	NULL

It	NULL
was	NULL
soon	NULL
found	NULL
to	NULL
also	NULL
take	NULL
part	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
regulating	NULL
IL-2	NULL
and	NULL
IL-2	NULL
«	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
NF-kB	NULL
Regulates	NULL
TCR-mediated	NULL
FasL	NULL
Expression	NULL
991	NULL
I	NULL
>	NULL
300	NULL
7	NULL
E	NULL
control	NULL
N	NULL
P+	NULL
!	NULL

BM	NULL
etoposide	NULL
bo	NULL
l	NULL
&	NULL
1	NULL
relative	NULL
luciferase	NULL
units	NULL
(	NULL
x103	NULL
)	NULL
n	NULL
&	NULL
&	NULL
0	NULL
hFasL	NULL
Pr	NULL
(	NULL
1.2	NULL
kb	NULL
)	NULL
+	NULL
+	NULL
B	NULL
DN-MEKK	NULL
=	NULL
+	NULL
0	NULL
3	NULL
E	NULL
control	NULL
N	NULL
P+I	NULL
207	NULL
107	NULL
relative	NULL
luciferase	NULL
units	NULL
(	NULL
x103	NULL
)	NULL
0	NULL
wI	NULL
mutant	NULL
T	NULL
T	NULL
A	NULL
G	NULL
T	NULL
C	NULL
A	NULL
G	NULL
GaT	NULL
o	NULL
TC	NULL
AT	NULL
wild	NULL
type	NULL
AP-1	NULL
mutant	NULL
-	NULL
AP-1	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

AP-1	NULL
is	NULL
not	NULL
obligatory	NULL
for	NULL
activation-induced	NULL
FasL	NULL
promoter	NULL
activity	NULL
.	NULL

A	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
hFasLPr	NULL
(	NULL
1.2	NULL
kb	NULL
)	NULL
and	NULL
DN-MEKK1	NULL
(	NULL
K432M	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
P+1	NULL
)	NULL
.	NULL

Reporter	NULL
activity	NULL
was	NULL
measured	NULL
after	NULL
12-16	NULL
h.	NULL
Results	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

B	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
the	NULL
1.2-kb	NULL
FasL	NULL
promoter	NULL
reporter	NULL
construct	NULL
or	NULL
a	NULL
construct	NULL
containing	NULL
the	NULL
mutation	NULL
in	NULL
the	NULL
AP-1	NULL
site	NULL
as	NULL
shown	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
determined	NULL
after	NULL
12-16	NULL
h.	NULL
receptor	NULL
genes	NULL
(	NULL
11	NULL
)	NULL
.	NULL

There	NULL
is	NULL
also	NULL
indirect	NULL
evidence	NULL
suggesting	NULL
that	NULL
NF-kB	NULL
can	NULL
be	NULL
involved	NULL
in	NULL
activation-induced	NULL
cell	NULL
death	NULL
(	NULL
20	NULL
,	NULL
31	NULL
)	NULL
.	NULL

AICD	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
inhibited	NULL
by	NULL
antioxidants	NULL
(	NULL
20	NULL
,	NULL
32	NULL
)	NULL
and	NULL
inhibitors	NULL
of	NULL
proteasome	NULL
activity	NULL
such	NULL
as	NULL
lactacys-tin	NULL
(	NULL
87	NULL
,	NULL
38	NULL
)	NULL
.	NULL

It	NULL
was	NULL
recently	NULL
shown	NULL
that	NULL
antioxidants	NULL
block	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
and	NULL
that	NULL
nondegradable	NULL
I	NULL
«	NULL
B	NULL
not	NULL
only	NULL
blocks	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
but	NULL
also	NULL
cell	NULL
death	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Thus	NULL
,	NULL
agents	NULL
that	NULL
induce	NULL
or	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
appear	NULL
to	NULL
have	NULL
an	NULL
impact	NULL
on	NULL
AICD	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
also	NULL
blocks	NULL
the	NULL
ability	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
to	NULL
induce	NULL
FasL	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Because	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
signaling	NULL
,	NULL
we	NULL
also	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
inhibiting	NULL
NF-kB	NULL
in	NULL
H	NULL
,	NULL
O	NULL
,	NULL
-induced	NULL
cell	NULL
death	NULL
and	NULL
found	NULL
that	NULL
inhibiting	NULL
NF-kB	NULL
blocks	NULL
this	NULL
mode	NULL
of	NULL
apoptosis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
has	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
signaling	NULL
events	NULL
that	NULL
prevent	NULL
cell	NULL
death	NULL
elicited	NULL
by	NULL
the	NULL
cytokine	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
,	NULL
TNFa	NULL
(	NULL
39	NULL
)	NULL
.	NULL

We	NULL
and	NULL
others	NULL
previously	NULL
showed	NULL
that	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
Jurkat	NULL
and	NULL
other	NULL
cell	NULL
types	NULL
sensitizes	NULL
these	NULL
cells	NULL
to	NULL
TNF	NULL
-induced	NULL
apoptosis	NULL
(	NULL
21	NULL
)	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
shown	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
also	NULL
prevents	NULL
DNA	NULL
damage	NULL
and	NULL
other	NULL
related	NULL
stress-induced	NULL
apoptosis	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
the	NULL
results	NULL
described	NULL
in	NULL
this	NULL
paper	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
seems	NULL
to	NULL
serve	NULL
multiple	NULL
functional	NULL
roles	NULL
under	NULL
different	NULL
conditions	NULL
.	NULL

Apoptosis	NULL
mediated	NULL
by	NULL
Fas	NULL
often	NULL
does	NULL
not	NULL
involve	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
40	NULL
)	NULL
.	NULL

On	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
TRAMP	NULL
(	NULL
TNF-related	NULL
apo-ptosis-mediating	NULL
protein	NULL
}	NULL
/DR3/WSL-1	NULL
and	NULL
TRAIL	NULL
receptors	NULL
(	NULL
TNF-related	NULL
apoptosis-inducing	NULL
ligand	NULL
)	NULL
induce	NULL
apoptosis	NULL
and	NULL
also	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
41-44	NULL
)	NULL
.	NULL

Like	NULL
FasL	NULL
,	NULL
TRAIL	NULL
is	NULL
also	NULL
induced	NULL
upon	NULL
lymphocyte	NULL
activation	NULL
,	NULL
and	NULL
its	NULL
expression	NULL
is	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
,	NULL
suggesting	NULL
a	NULL
role	NULL
for	NULL
calcineurin	NULL
and	NULL
NF-AT	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Whether	NULL
NF-	NULL
«	NULL
B	NULL
also	NULL
regulates	NULL
TRAIL	NULL
expression	NULL
is	NULL
not	NULL
known	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
some	NULL
of	NULL
the	NULL
early	NULL
signals	NULL
may	NULL
define	NULL
the	NULL
de	NULL
novo	NULL
gene	NULL
expression	NULL
.	NULL

Our	NULL
present	NULL
study	NULL
also	NULL
raises	NULL
some	NULL
interesting	NULL
questions	NULL
about	NULL
the	NULL
complex	NULL
regulation	NULL
of	NULL
Fas	NULL
ligand	NULL
.	NULL

A	NULL
0.9	NULL
kb	NULL
fragment	NULL
of	NULL
the	NULL
FasL	NULL
reporter	NULL
had	NULL
low	NULL
activity	NULL
upon	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

1C	NULL
)	NULL
,	NULL
whereas	NULL
a	NULL
486-bp	NULL
reporter	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
sufficient	NULL
for	NULL
reporter	NULL
activity	NULL
(	NULL
10	NULL
)	NULL
.	NULL

One	NULL
possibility	NULL
is	NULL
that	NULL
there	NULL
could	NULL
be	NULL
repressor	NULL
elements	NULL
in	NULL
the	NULL
Fas	NULL
ligand	NULL
promoter	NULL
that	NULL
may	NULL
act	NULL
as	NULL
regulators	NULL
of	NULL
this	NULL
death-promoting	NULL
gene	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
on	NULL
human	NULL
FasL	NULL
promoter	NULL
has	NULL
suggested	NULL
the	NULL
existence	NULL
of	NULL
a	NULL
repressor	NULL
element	NULL
between	NULL
-453-373	NULL
in	NULL
the	NULL
promoter	NULL
(	NULL
46	NULL
)	NULL
.	NULL

This	NULL
study	NULL
did	NULL
not	NULL
,	NULL
however	NULL
,	NULL
characterize	NULL
the	NULL
region	NULL
between	NULL
-473	NULL
and	NULL
-2365	NULL
in	NULL
the	NULL
promoter	NULL
.	NULL

Our	NULL
study	NULL
suggests	NULL
the	NULL
possibility	NULL
of	NULL
a	NULL
repressor	NULL
element	NULL
between	NULL
-900	NULL
and	NULL
-486	NULL
bp	NULL
in	NULL
this	NULL
promoter	NULL
,	NULL
and	NULL
there	NULL
could	NULL
also	NULL
be	NULL
another	NULL
between	NULL
the	NULL
1.2	NULL
kb	NULL
and	NULL
the	NULL
2.3	NULL
kb	NULL
of	NULL
the	NULL
enhancer	NULL
.	NULL

We	NULL
are	NULL
currently	NULL
analyzing	NULL
the	NULL
promoter	NULL
region	NULL
for	NULL
any	NULL
such	NULL
repressor	NULL
elements	NULL
.	NULL

It	NULL
is	NULL
also	NULL
interesting	NULL
that	NULL
NF-AT	NULL
alone	NULL
is	NULL
sufficient	NULL
to	NULL
drive	NULL
a	NULL
486-bp	NULL
FasL	NULL
promoter	NULL
(	NULL
10	NULL
)	NULL
,	NULL
whereas	NULL
in	NULL
the	NULL
context	NULL
of	NULL
a	NULL
1.2-kb	NULL
promoter	NULL
,	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
NF-AT	NULL
site	NULL
did	NULL
not	NULL
completely	NULL
inhibit	NULL
the	NULL
promoter	NULL
activity	NULL
.	NULL
``	NULL

In	NULL
contrast	NULL
,	NULL
a	NULL
mutation	NULL
in	NULL
the	NULL
NF-kB	NULL
site	NULL
had	NULL
a	NULL
profound	NULL
effect	NULL
on	NULL
activation-induced	NULL
Fas	NULL
ligand	NULL
promoter	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
critical	NULL
for	NULL
FasL	NULL
expression	NULL
.	NULL

So	NULL
far	NULL
,	NULL
NF-kB	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
NF-AT	NULL
are	NULL
among	NULL
the	NULL
transcription	NULL
factors	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
some	NULL
forms	NULL
of	NULL
apoptosis	NULL
,	NULL
of	NULL
which	NULL
NF-	NULL
«	NULL
B	NULL
seems	NULL
to	NULL
possess	NULL
quite	NULL
distinct	NULL
characteristics	NULL
.	NULL

Understanding	NULL
the	NULL
characteristics	NULL
of	NULL
this	NULL
molecule	NULL
with	NULL
regard	NULL
to	NULL
how	NULL
this	NULL
differential	NULL
specificity	NULL
is	NULL
achieved	NULL
and	NULL
how	NULL
different	NULL
signaling	NULL
events	NULL
converge	NULL
on	NULL
the	NULL
same	NULL
regulatory	NULL
factor	NULL
would	NULL
also	NULL
shed	NULL
light	NULL
on	NULL
any	NULL
``	NULL
switch	NULL
mechanism	NULL
``	NULL
a	NULL
cell	NULL
might	NULL
have	NULL
to	NULL
regulate	NULL
different	NULL
cellular	NULL
functions	NULL
.	NULL

We	NULL
studied	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
previously	NULL
identified	NULL
AP-1	NULL
site	NULL
(	NULL
16	NULL
)	NULL
in	NULL
T	NULL
cell	NULL
activation-mediated	NULL
FasL	NULL
expression	NULL
and	NULL
found	NULL
that	NULL
AP-1	NULL
was	NULL
dispensable	NULL
for	NULL
this	NULL
form	NULL
of	NULL
induction	NULL
but	NULL
was	NULL
required	NULL
for	NULL
induction	NULL
by	NULL
stress	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Our	NULL
studies	NULL
indicate	NULL
that	NULL
the	NULL
preference	NULL
of	NULL
different	NULL
transcription	NULL
factors	NULL
to	NULL
regulate	NULL
gene	NULL
transcription	NULL
varies	NULL
with	NULL
the	NULL
mode	NULL
of	NULL
cell	NULL
activation	NULL
.	NULL

The	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
are	NULL
involved	NULL
in	NULL
stress-induced	NULL
FasL	NULL
expression	NULL
,	NULL
whereas	NULL
NF-AT	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
appear	NULL
to	NULL
cooperate	NULL
in	NULL
T	NULL
cell	NULL
receptor-mediated	NULL
FasL	NULL
expression	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
Yoo	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
LaFace	NULL
,	NULL
D.	NULL
,	NULL
Ware	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

9	NULL
,	NULL
1017-1026	NULL
2	NULL
.	NULL

Brunner	NULL
,	NULL
T.	NULL
,	NULL
Mogil	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
LaFace	NULL
,	NULL
D.	NULL
,	NULL
Yoo	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Mahboubi	NULL
,	NULL
A.	NULL
,	NULL
Echeverri	NULL
,	NULL
F.	NULL
,	NULL
Martin	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Force	NULL
,	NULL
W.	NULL
R.	NULL
,	NULL
Lynch	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Ware	NULL
,	NULL
C.	NULL
F.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
441-444	NULL
3	NULL
.	NULL

Alderson	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Tough	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
Davis-Smith	NULL
,	NULL
T.	NULL
,	NULL
Braddy	NULL
,	NULL
S.	NULL
,	NULL
Falk	NULL
,	NULL
B.	NULL
,	NULL
Schooley	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Goodwin	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
Smith	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
Ramsdell	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Lynch	NULL
,	NULL
D.	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
71-77	NULL
4	NULL
.	NULL

Dhein	NULL
,	NULL
J.	NULL
,	NULL
Walczak	NULL
,	NULL
H.	NULL
,	NULL
Baumler	NULL
,	NULL
C.	NULL
,	NULL
Debatin	NULL
,	NULL
K.-M.	NULL
,	NULL
and	NULL
Krammer	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
488-441	NULL
.	NULL

Ju	NULL
,	NULL
S.-T.	NULL
,	NULL
Panka	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Cui	NULL
,	NULL
H.	NULL
,	NULL
Ettinger	NULL
,	NULL
R.	NULL
,	NULL
El-Khatib	NULL
,	NULL
M.	NULL
,	NULL
Sherr	NULL
,	NULL
D.	NULL
H.	NULL
,	NULL
Stanger	NULL
,	NULL
B	NULL
.	NULL

Z.	NULL
,	NULL
and	NULL
Marshak-Rothstein	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
444-448	NULL
.	NULL

Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Littman	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
263-274	NULL
.	NULL

Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
695-697	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
15	NULL
,	NULL
274-281	NULL
.	NULL

Rothenberg	NULL
,	NULL
E.	NULL
V.	NULL
,	NULL
and	NULL
Ward	NULL
,	NULL
S.	NULL
B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
9358	NULL
10	NULL
.	NULL

Latinis	NULL
,	NULL
K.	NULL
,	NULL
Norian	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Eliason	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Koretzky	NULL
,	NULL
G.	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

gr	NULL
t	NULL
go	NULL
®	NULL
*	NULL
8	NULL
.	NULL

Kasibhatla	NULL
,	NULL
unpublished	NULL
observations	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
992	NULL
11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24.	NULL
.	NULL

Henkel	NULL
,	NULL
T.	NULL
,	NULL
Zabel	NULL
,	NULL
U.	NULL
,	NULL
van	NULL
Zee	NULL
,	NULL
K.	NULL
,	NULL
Muller	NULL
,	NULL
J.	NULL
,	NULL
Fanning	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Bacuerle	NULL
,	NULL
P.	NULL
26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

Chem	NULL
.	NULL

272	NULL
,	NULL
81427-81484	NULL
Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
Lowenthal	NULL
,	NULL
J.	NULL
W.	NULL
,	NULL
Sieckewitz	NULL
,	NULL
M.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Franza	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
827-836	NULL
Shibuya	NULL
,	NULL
H.	NULL
,	NULL
Yoneyama	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Taniguchi	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

1	NULL
,	NULL
48-49	NULL
Bacuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
649-681	NULL
Mercurio	NULL
,	NULL
F.	NULL
,	NULL
Zhu	NULL
,	NULL
H.	NULL
,	NULL
Murray	NULL
.	NULL

B.	NULL
W.	NULL
,	NULL
Shevchenko	NULL
,	NULL
A.	NULL
,	NULL
Bennett	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
Li	NULL
,	NULL
J.	NULL
,	NULL
Young	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Barbosa	NULL
,	NULL
M.	NULL
,	NULL
Mann	NULL
,	NULL
M.	NULL
,	NULL
Manning	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
860-866	NULL
Kasibhatla	NULL
,	NULL
S.	NULL
,	NULL
Brunner	NULL
,	NULL
S.	NULL
,	NULL
Genestier	NULL
,	NULL
G.	NULL
,	NULL
Echeverri	NULL
,	NULL
E.	NULL
,	NULL
Mahboubi	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
1	NULL
,	NULL
548-551	NULL
Kasibhatla	NULL
,	NULL
S.	NULL
,	NULL
Nalefski	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

151	NULL
,	NULL
3140-8151	NULL
DiDonato	NULL
,	NULL
J.	NULL
,	NULL
Mercurio	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
1295-1304	NULL
Mercurio	NULL
,	NULL
F.	NULL
,	NULL
DiDonato	NULL
,	NULL
J.	NULL
,	NULL
Rossette	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
705-718	NULL
Bauer	NULL
,	NULL
M.	NULL
K.	NULL
A.	NULL
,	NULL
Vogt	NULL
,	NULL
M.	NULL
,	NULL
Los	NULL
,	NULL
M.	NULL
,	NULL
Siegel	NULL
,	NULL
J.	NULL
,	NULL
Wesselborg	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Schulze-Osthoff	NULL
,	NULL
K.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

2783	NULL
,	NULL
8048-8053	NULL
Van	NULL
Antwerp	NULL
,	NULL
D.	NULL
,	NULL
Martin	NULL
,	NULL
S.	NULL
,	NULL
Kafri	NULL
,	NULL
T.	NULL
,	NULL
Green	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
187-789	NULL
Beg	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
782-784	NULL
Wang	NULL
,	NULL
C.-U	NULL
.	NULL

,	NULL
Mayo	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Science	NULL
274	NULL
,	NULL
784-787	NULL
Liu	NULL
,	NULL
Z.-G.	NULL
,	NULL
Hsu	NULL
,	NULL
H.	NULL
,	NULL
Goeddel	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Cell	NULL
87	NULL
,	NULL
565-576	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
68	NULL
,	NULL
1121-1133	NULL
Lin	NULL
,	NULL
Y.-Z	NULL
.	NULL

,	NULL
Yao	NULL
,	NULL
S.	NULL
,	NULL
Veach	NULL
,	NULL
R.	NULL
,	NULL
Torgerson	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Hawiger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
14255-14258	NULL
Brunner	NULL
,	NULL
T.	NULL
,	NULL
Yoo	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
Griffith	NULL
,	NULL
T.	NULL
S.	NULL
,	NULL
Ferguson	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Green	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
Behring	NULL
Inst	NULL
.	NULL

Mitt	NULL
.	NULL

97	NULL
,	NULL
161-174	NULL
Rossette	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

128	NULL
,	NULL
1111-1119	NULL
Lenardo	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
227-229	NULL
30	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45.	NULL
.	NULL

Holtz-Heppelmann	NULL
,	NULL
C.	NULL
,	NULL
Algeciras	NULL
,	NULL
A.	NULL
,	NULL
Badley	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Paya	NULL
,	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

NF-kB	NULL
Regulates	NULL
TCR-mediated	NULL
FasL	NULL
Expression	NULL
Lin	NULL
,	NULL
S.-H.	NULL
,	NULL
Wortis	NULL
,	NULL
H.	NULL
W.	NULL
,	NULL
and	NULL
Stavnezer	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
5528-5532	NULL
.	NULL

Ivanov	NULL
,	NULL
V.	NULL
,	NULL
Lee	NULL
,	NULL
R.	NULL
,	NULL
Podack	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Malek	NULL
,	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
Oncogene	NULL
22	NULL
,	NULL
2455-2464	NULL
.	NULL

Williams	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Henkart	NULL
,	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

157	NULL
,	NULL
2895-2402	NULL
.	NULL

Ballard	NULL
,	NULL
D.	NULL
,	NULL
Dixon	NULL
,	NULL
E.	NULL
,	NULL
Peffer	NULL
,	NULL
N.	NULL
,	NULL
Bogerd	NULL
,	NULL
H.	NULL
,	NULL
Doerre	NULL
,	NULL
S.	NULL
,	NULL
Stein	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Greene	NULL
,	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
1875-1879	NULL
.	NULL

Su	NULL
,	NULL
B.	NULL
,	NULL
Jacinto	NULL
,	NULL
E.	NULL
,	NULL
Hibi	NULL
,	NULL
M.	NULL
,	NULL
Kallunki	NULL
,	NULL
T.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ben-Neriah	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
77	NULL
,	NULL
727-736	NULL
.	NULL

Minden	NULL
,	NULL
A.	NULL
,	NULL
Lin	NULL
,	NULL
A.	NULL
,	NULL
McMahon	NULL
,	NULL
M.	NULL
,	NULL
Carter	NULL
,	NULL
C.	NULL
,	NULL
Derijard	NULL
,	NULL
B.	NULL
,	NULL
Davis	NULL
,	NULL
R.	NULL
,	NULL
Johnson	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Science	NULL
266	NULL
,	NULL
1719-1723	NULL
.	NULL

Sen	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1986	NULL
)	NULL
Cell	NULL
46	NULL
,	NULL
705-716	NULL
.	NULL

Matsui	NULL
,	NULL
K.	NULL
,	NULL
Omura	NULL
,	NULL
S.	NULL
,	NULL
Cui	NULL
,	NULL
H.	NULL
,	NULL
Schauer	NULL
,	NULL
S.	NULL
,	NULL
Sonenshein	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Ju	NULL
,	NULL
S-T	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27	NULL
,	NULL
2269-2278	NULL
Cui	NULL
,	NULL
H.	NULL
,	NULL
Matsui	NULL
,	NULL
K.	NULL
,	NULL
Omura	NULL
,	NULL
S.	NULL
,	NULL
Schauer	NULL
,	NULL
S.	NULL
,	NULL
Matulka	NULL
,	NULL
R.	NULL
,	NULL
Sonenshein	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Ju	NULL
,	NULL
S.-T.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

94	NULL
,	NULL
7515-7520	NULL
Finco	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunity	NULL
8	NULL
,	NULL
263-272	NULL
Pan	NULL
,	NULL
G.	NULL
,	NULL
O'Rourke	NULL
,	NULL
K.	NULL
,	NULL
Chinnaiyan	NULL
,	NULL
A.	NULL
,	NULL
Gentz	NULL
,	NULL
R.	NULL
,	NULL
Ebner	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Dixit	NULL
,	NULL
V.	NULL
(	NULL
1997	NULL
)	NULL
Science	NULL
276	NULL
,	NULL
111-118	NULL
Wiley	NULL
,	NULL
S.	NULL
,	NULL
Schooley	NULL
,	NULL
K.	NULL
,	NULL
Smolak	NULL
,	NULL
P.	NULL
,	NULL
Din	NULL
,	NULL
W.	NULL
,	NULL
Huang	NULL
,	NULL
C.	NULL
,	NULL
Nicoll	NULL
,	NULL
J.	NULL
,	NULL
Sutherland	NULL
,	NULL
G.	NULL
,	NULL
Smith	NULL
,	NULL
T.	NULL
,	NULL
Rauch	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Smith	NULL
,	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
Immunity	NULL
8	NULL
,	NULL
678-682	NULL
Chaudhary	NULL
,	NULL
P.	NULL
,	NULL
Eby	NULL
,	NULL
M.	NULL
,	NULL
Jasmin	NULL
,	NULL
A.	NULL
,	NULL
Bookwalter	NULL
,	NULL
A.	NULL
,	NULL
Murray	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Hood	NULL
,	NULL
L.	NULL
(	NULL
1997	NULL
)	NULL
Immunity	NULL
7	NULL
,	NULL
821-830	NULL
Degli-Esposti	NULL
,	NULL
M.	NULL
,	NULL
Dougall	NULL
,	NULL
W.	NULL
,	NULL
Smolak	NULL
,	NULL
P.	NULL
,	NULL
Waugh	NULL
,	NULL
J.	NULL
,	NULL
Smith	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Goodwin	NULL
,	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
Immunity	NULL
7	NULL
,	NULL
813-820	NULL
.	NULL

Schneider	NULL
,	NULL
P.	NULL
,	NULL
Thome	NULL
,	NULL
M.	NULL
,	NULL
Burns	NULL
,	NULL
K.	NULL
,	NULL
Bodmer	NULL
,	NULL
J.-L.	NULL
,	NULL
Hofman	NULL
,	NULL
K.	NULL
,	NULL
Kataoka	NULL
,	NULL
T.	NULL
,	NULL
Holler	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Tschopp	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Immunity	NULL
7	NULL
,	NULL
881-836	NULL
Mariani	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Krammer	NULL
,	NULL
P.	NULL
(	NULL
1998	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

28	NULL
,	NULL
1492-1498	NULL
Chem	NULL
.	NULL

278	NULL
,	NULL
4416-4423	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Regulation	NULL
of	NULL
Fas-Ligand	NULL
Expression	NULL
during	NULL
Activation-induced	NULL
Cell	NULL
Death	NULL
in	NULL
T	NULL
Lymphocytes	NULL
via	NULL
Nuclear	NULL
Factor	NULL
<	NULL
B	NULL
Shailaja	NULL
Kasibhatla	NULL
,	NULL
Laurent	NULL
Genestier	NULL
and	NULL
Douglas	NULL
R.	NULL
Green	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1999	NULL
,	NULL
274:987-992.	NULL
doi	NULL
:	NULL
10.1074/jb0.274.2.987	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/274/2/987	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
46	NULL
references	NULL
,	NULL
19	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
.full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

